Physician profile
Stephen A Davis
NPI 1285675710
$6,649.60
in general payments reported to CMS, 2019-2025
36 companies · $793 in 2025
The $793 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $963 · 2021: $1,368 · 2022: $1,064 · 2023: $675 · 2024: $882 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,349.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,248.86 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $838.73 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $569.36 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $548.38 | 2021-2025 | |
| Lilly USA, LLC | $369.71 | 2019-2024 | Mounjaro, Jardiance |
| Amgen INC. | $290.50 | 2019-2025 | Tepezza, Evenity, Repatha |
| Medtronic, INC. | $234.84 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Amarin Pharma, INC. | $182.15 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $165.92 | 2019-2022 | |
| Corcept Therapeutics | $164.65 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $124.99 | 2021-2025 | Gvoke Hypopen |
| Abbvie INC. | $116.77 | 2021-2025 | |
| Becton, Dickinson and Company | $111.18 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.42 | 2020-2025 | Jardiance |
| Insulet Corporation | $62.33 | 2019 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.